Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference, scheduled for September 14-16, 2026, in New York City, is a key event for the investment community, and Helus Pharma's participation signals its growing prominence in the biotech sector.
The fireside chat, slated for September 14 at 9 a.m. EDT, will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. This appearance offers investors and analysts an opportunity to gain insights into the company's strategic direction and clinical progress. Helus Pharma is currently advancing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD), which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder (GAD). These programs address significant unmet needs in mental health, a market that continues to expand as the global burden of depression and anxiety rises.
The significance of this announcement extends beyond a conference appearance. It underscores Helus Pharma's commitment to developing innovative treatments that could transform the mental health landscape. The company's focus on NSAs—synthetic molecules designed to activate serotonin pathways and promote neuroplasticity—represents a novel approach compared to traditional antidepressants, which often have delayed onset and limited efficacy. By targeting the underlying mechanisms of mental health disorders, Helus Pharma aims to provide durable improvements, potentially offering new hope to patients who do not respond to existing therapies.
Helus Pharma's involvement in the H.C. Wainwright conference also highlights its visibility among institutional investors and industry stakeholders. Such platforms are crucial for emerging biotech firms to secure funding and partnerships necessary for advancing clinical trials and eventual commercialization. The company's recent milestones, including the FDA's Breakthrough Therapy Designation for HLP003, have likely contributed to its credibility and attractiveness to investors.
Moreover, the conference comes at a time when the mental health sector is experiencing heightened interest, driven by increased awareness and the economic impact of mental illness. The global market for depression and anxiety treatments is projected to grow significantly, and Helus Pharma's pipeline positions it to capitalize on this trend. The company's operations in Canada, the United States, the United Kingdom, and Ireland give it a broad reach for future clinical trials and market access.
Investors and stakeholders can monitor the company's progress through its investor relations website, where the webcast replay will be available. For more information about Helus Pharma and its development programs, visit Helus Pharma's website or follow the team on X, LinkedIn, YouTube, and Instagram.
